Travere Therapeutics is stepping up its rare kidney disease pipeline by paying Everest Medicines $112.5 million upfront for a drug program targeting a broader set of rare kidney indications beyond Travere’s approved Filspari. The transaction is structured to support clinical development as Travere expands beyond its existing portfolio. A separate, related coverage piece highlighted Travere’s planned scaling of its partnership with Everest, underscoring the company’s intent to deepen its rare disease footprint while continuing to develop late-stage and emerging candidates. Financial terms beyond the upfront were not fully detailed in the provided excerpts. The deal signals continued investor and corporate appetite for kidney portfolios, where differentiated mechanisms and biomarker-led programs can drive meaningful clinical and commercial differentiation.